

ChemComm

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

COMMUNICATION

Ready Display of Antigenic Peptides in a Protein 'Mimogen'[†]

Received 00th January 2012,
Accepted 00th January 2012

DOI: 10.1039/x0xx00000x

www.rsc.org/

M. Robert J. Vallée^a, Matthew W. Schombs^a, Zack J. Balaban^{b,c}, John Colyer^{b,c*} and Benjamin G. Davis^{a*}

Given the dependence of much modern biology upon the use of antibodies as tools and reagents, their variability and the often associated lack-of-detail about function and identity creates experimental errors. Here we describe the proof-of-principle for a potentially general, versatile method for the display of antigens in a soluble yet standard format on a lateral protein scaffold that mimics normal epitopes in a protein antigen (a 'mimogen') and confirm their utility in phosphorylation-dependent recognition by specific antibodies.

The general adoption over > 35 years of gel-based analytical techniques for the identification of proteins using specific antibodies (Abs)^{1,2} (so-called "Western blotting") has led to its use as a mainstay technique in biological sciences. There is now a vast array of Abs available from different sources, with variable amounts of associated characterization data.^{3,4} For example, commercial sources may have little or no data on breadth of target epitopes/antigens ('cross-reactivity') or antibody sequence from which serious scientific issues may arise. It also reduces productivity as end users frequently need to screen many antibodies before a reliable one can be found for a particular biomarker and/or system. The low standards of Ab characterisation also contributes to the significant economic cost of irreproducible pre-clinical research, which has been estimated at \$28Bn per annum for pre-clinical research in USA alone.^{5,6} Most researchers use western blotting as a qualitative technique capable of identifying a biomarker of interest, or as a semi-quantitative technique to examine the relative quantity of the same biomarker in separate biological specimens. However, with the inclusion of an appropriate calibration standard, western blotting can potentially generate quantitative data for a given biomarker (enabling estimation of, for example, protein amount and even extent of structural alteration).⁷⁻⁹ It also validates the utility of the Ab against that calibrant in a direct manner. A general method that would allow fast and efficient screening of antibody binding specificity and calibration through the display of target epitopes on a standard protein platform would therefore be a potentially powerful tool.

We considered that one method for generating epitopes displayed in a scaffold with protein-like properties (allowing ready use of e.g., gel electrophoresis, protein quantification dyes as well as other associated well-developed protein techniques) would be to create a generalizable protein platform onto which epitope peptides could be laterally grafted covalently (Fig. 1). This would avoid the necessity to create a bespoke protein appropriately displaying the epitope on each associated occasion that a calibrant was required (through, e.g., creation of a fusion protein or other display-dependent methods)¹⁰ and would permit the display of epitopes with precise post-translational modifications as required. It would also avoid any associated complications that might stem from the influence of the display method or scaffold on secondary/tertiary structure that might arise from linear display in this way (Fig. 1a). We envisaged that such a 'lateral display' system might allow the efficient mimicry of epitope(s) as part of a greater protein as a pseudo-antigen that might be called a 'mimogen' (a mimicking antigen, by reference to 'mimotopes'¹¹ [1]). Advantageously, a common protein platform would allow similar, modular methods for construction and common functional (e.g., macromolecular) properties (Fig 1b); this would allow rapid and economic construction of large numbers of such mimogens, as is required for large-scale systems biology research programmes.





Figure 1: General concept (b) for the precise ‘lateral’ display of antigenic mimotope peptides **1** and **2** on a protein scaffold that would avoid potential issues of context dependency created by current linear, fusion display methods (a), such as perturbation of secondary structure.

As a test system we chose one of the most vital and functionally wide-ranging post-translational modifications: protein phosphorylation. Phospholamban (PLN) regulates the sarco(endo)plasmic reticulum calcium ATP-ase (SERCA) pump in cardiac and skeletal muscle cells through a mechanism governed by its phosphorylation state.¹²⁻¹⁴ As such, PLN plays a crucial role in the physiological regulation of cardiac contractility and hence a vital role in human biology. PLN is a 52 amino acid membrane protein that exists in monomeric and homopentameric forms that can be difficult to generate as readily controllable standards or calibrants.¹⁵ The simple structure and known sites of phosphorylation suggested PLN as an ideal candidate for the mimogen approach.

Phosphorylation site-specific Abs have been produced to PLN, which discriminate between Ser-16 phosphorylated and unphosphorylated PLN.¹⁶ These and other Abs (that recognise PLN in all states of phosphorylation) have been used to gain a qualitative and semi-quantitative understanding of the role PLN in stress responses in the heart.¹⁷ The epitope sequences of Abs to PLN overlap considerably: a monoclonal Ab A1, that is used routinely to measure total protein, recognises residues 7-16 on PLN, where Leu7 is the most important determinant.¹² Putative phospho-specific antibody PS-16 was raised to an 11 amino acid fragment of PLN (residues 9-19 RSAIRRA_{S16}TIE) peptide built of residues 9-19, where Ser at position 16 was phosphorylated.¹⁶



Scheme 1 Conjugation of antigenic mimotope peptide to Npβ scaffold.

Peptides **1** and **2** (see Figure 1 for sequences) containing a key segment of PLN in unmodified and phosphorylated states, respectively, were designed and synthesized using essentially standard solid-phase peptide synthesis techniques (see below and SI). As an appropriate scaffold for the attachment of these antigenic mimotopes a protein with regular motif, moderate molecular weight and good stability as well as non-perturbing activity and structure was required. The fused pentapeptide repeat protein (PRP) Np275/Np276¹⁸ (commonly referred to as Np276 or Npβ) was chosen as a potentially ideal scaffold that

met this criteria; in particular, its ordered beta-sheets arrayed in a repeating cuboid geometry,¹⁹ we reasoned could be exploited for controlled display of antigens, with the potential for extended, multivalency and even distance-control. In addition, it displays minimal non-specific binding properties, likely as a function of its unusual structure, balanced hydrophobicity/philicity and lack of singular motifs.

1 and **2** were precisely displayed on Npβ through a ‘tag-and-modify’²⁰ approach; here through post-expression installation of a selectively reactive chemical group into the protein, the ‘tag’, followed by the selective modification of this new group. Our group and others have developed versatile protocol for the selective formation of the dehydroalanine (Dha) tag in proteins genetically, biosynthetically and chemically,²¹⁻²⁴ as a usefully selective conjugate electrophile.

Model scaffold mutant protein Npβ-G2F-M61C (**3**) was expressed in *E. coli* BL21(DE3) (at 16 °C) as designed mutant resistant to *N*-terminal *N*-glucosylation²⁵ (by virtue of G2F) and readily converted to Dha61 following expression (by virtue of M61C as a sole Cys). After expression, **3** was treated with 2,5-dibromohexanediamide (DBHDA)²⁴ to yield the ‘tag-bearing scaffold **4** protein Npβ-G2F-Dha61 (Scheme 1 and Figure 2). Peptides **1** and **2** proved to be challengingly bulky conjugate nucleophiles, larger than many previous nucleophiles reacted with Dha in proteins. A thiol group with a relatively low pK_a of ~8 (1-2 units lower than the typical pK_a of alkyl thiols²⁶) was designed into **1** and **2** via a cysteinylated-spacer-motif (based upon gamma-aminobutyric acid) to favour conjugate addition as a thiolate or readily deprotonated thiol. Advantageously, the entire unit was prepared from commercially-available building blocks using standard Fmoc-based methods.

Table 1 Optimization of conjugation of Npβ scaffold with antigenic peptides

Entry	Peptide	Buffer (50 mM)	pH	T (°C)	Y (%) ^a
1	1	phosphate	8	30	56%
2	1	phosphate (+ guanidine 3M)	8	30	35%
3	1	tris / HCl	8	30	21%
4	1	tris / HCl	9	22	34%
5	1	tris / HCl	9	30	63%
6	1	borax	9	22	39%
7	1	borax	10	22	60%
8	1	borax	10	30	93%
9	2	phosphate	8	30	9%
10	2	borax ^b	10	30	43%

^a determined by LCMS, reaction time 1.5h ^b reaction time 5h

Precise conjugation between the antigenic mimotope **1** and **2** and protein scaffold **4** (Scheme 1) was tested under conditions of varying temperature, buffer systems (phosphate, tris / HCl and borax) and pH (values between 8.0 and 10.0) (Table 1). At lower pH, phosphate buffer proved superior to tris / HCl or borax buffer (Table 1) but conversion was more positively affected by a higher pH. Notably, addition of denaturing reagents (e.g., 3M guanidine•HCl) did not lead to an

improvement in product formation, suggesting that reactivity was not dependent on the protein scaffold tertiary structure and that the scaffold is non-interfering in both chemistry and display. Optimal conditions (borax buffer (50 mM), 30 °C pH 10) allowed ready conversion of Np β -G2F-Dha61 (**4**) to desired unphosphorylated protein-peptide conjugate Np β -PLN₂₋₁₉ **5** (>90 %, Table 1, Entry 8 and Figure 2).




Figure 2: LCMS analysis of conversion of Np β -G2F-M61C (**3**) to Np β -Dha61 (**4**) and then reaction to give antigenic mimogen peptide-protein conjugate **5**.

Application of the same procedure also allowed successful conjugation of the phosphorylated antigenic mimotope peptide **2** onto **4** to give protein-peptide conjugate **6** under the same reaction conditions (Scheme 1) without side-product formation, albeit with more sluggish conversion requiring prolonged reaction times (Table 1 and SI). Advantageously, due to the large mass difference between **4** and **6** and the lack of side products, **6** could be readily separated from **4** by HPLC or size exclusion chromatography, allowing possible recycling.




Figure 3 Western blot analysis showed binding of a) Ab A1 and b) Ab PS-16 towards five proteins: negative control protein DBK1 (lane 1), PLN (lane 2), phosphoPLN (lane 3), and crude mimogen conjugates **5** (lane 4) and **6** (lane 5). Reference mass markers have been superimposed. Gels shown directly from image scan with only coded labels added as registration markers. Red boxes highlight mimogens.

With unphosphorylated and phosphorylated antigenic mimogen conjugates **5** and **6** in hand, we tested both ‘mimogens’ in crude western blot analysis to examine the binding specificity of antibodies A1 (total PLN) and PS-16 (anti-PLN pSer16). The monoclonal Ab A1 to PLN recognised both unphosphorylated (PLN) and phosphorylated PLN (pPLN) proteins (sarcolemmal reticulum (SR) samples: control and PKA

treated respectively; Figure 3a, lanes 2,3) and phosphorylated and unphosphorylated mimogens **5** and **6**. However, it displayed a clear preference for unphosphorylated mimogen **5** (Figure 3a, lane 4 vs 5) consistent with the intended efficient mimicry of **5** of unphosphorylated PLN. The binding specificity of the pSer16 phospho-specific Ab PS-16 was examined on the *same* western blot membrane, after removing the A1 complexes. This Ab discriminated between unphosphorylated and Ser16 phosphorylated (pSer16) protein (Figure 3b, lanes 2,3) and mimogens **5** and **6** (Figure 3b, lanes 4,5), providing a signal only with phosphorylated epitope samples, again consistent with the designed mimogen system. The naked mimogen scaffold (Np β -G2F-Dha61) was not detected by either antibody, further confirming its suitability as a display scaffold. Thus, even in this crude, re-used format, immediate and clear readout could be obtained directly from quick and ready reactive use of the scaffold to create mimogens.

Conclusions

Together, these initial data confirmed the design and utility of this protein scaffold system as a potentially suitable ‘neutral’ display system for antigenic detection of model mimotope peptides that here allow clear detection and discrimination of the modification state of a single contextual phosphorylation site (Ser16 in PLN), despite not being displayed in a native protein context.

One advantage of the Dha tag is its versatility in diverse elaboration, making it a potentially useful strategy for the elaboration of a single protein scaffold in several functionally discriminatory directions (here pSer vs Ser). Here, a readily produced peptide motif could be directly conjugated following automated synthesis with a stable but reactive protein scaffold **4** to give differentiated peptide-protein conjugate mimogens directly. Although high levels of conjugation (>90%) were achievable, we also demonstrated that since the chemistry for conjugation is usefully clean, gel electrophoresis provides a method for separation that allows the use of even partially reacted samples. As such, it is a proof-of-principle that may offer a general method for ‘quick-and-easy’ access to protein-like antigens (termed here ‘mimogens’), even for incompletely reacted samples, without requiring specialist knowledge of protein chemistry methods. In this way, we believe that this method might not only provide the ‘non-expert’ with valuable antigenic alternatives for proteins not currently accessible by direct expression methods but also a highly desirable ‘kit-like’ system for quick and cheap reference alternatives in western blotting experiments⁷⁻⁹ or other protein antigen contexts.

Notes and references

^a Chemistry Research Laboratory, University of Oxford, 12 Mansfield Road, Oxford, OX1 3TA, UK. E-mail: Ben.Davis@chem.ox.ac.uk

^b Badrilla Ltd., Leeds Innovation Centre, 103 Clarendon Road, Leeds LS2 9DF, UK

^c School of Biomedical Science, University of Leeds, Leeds LS2 9JT, UK. E-mail: J.Colyer@leeds.ac.uk

[†] Electronic Supplementary Information (ESI) available. See DOI: 10.1039/c000000x/.

ø JC founded and has a financial interest in Badrilla Ltd. JC is an inventor on a patent related to mimogens. MS, JC, BGD developed the concepts. RV, MS, JC, BGD, designed the experimental systems. MS, RV, ZJB performed experiments. Mimogen western analysis was performed at Badrilla and by ZJB. All analysed the results. RV, MS, JC, BGD wrote the manuscript. All read and commented on the manuscript.

□ Whilst the term antigen has gained more generalized usage with broader context, we use here the term antigen in a manner consistent with its original definition (it originally described a structural molecule that binds specifically to an antibody) and that adopted by IUPAC (Gold Book; a substance that stimulates the immune system to produce a set of specific antibodies and that combines with the antibody through a specific binding site or epitope). In this context we therefore use it here to describe the intact molecular ligand for an antibody and it should be properly contrasted with the term adopted by IUPAC for immunogen (Gold Book; a substance that elicits a cellular immune response and/or antibody production).

Acknowledgements

We thank the EPSRC for funding (EP/I500200/1 and EP/K503769/1)

1. J. Renart, J. Reiser and G. R. Stark, *Proceedings of the National Academy of Sciences of the United States of America*, 1979, **76**, 3116-3120.
2. H. Towbin, T. Staehelin and J. Gordon, *Proceedings of the National Academy of Sciences of the United States of America*, 1979, **76**, 4350-4354.
3. M. Baker, *Nature*, 2015, **521**, 274-276.
4. A. Bradbury and A. Pluckthun, *Nature*, 2015, **518**, 27-29.
5. I. M. C. Leonard P. Freedman, Timothy S. Simcoe *PLoS Biology*, 2015, 10.1371/journal.pbio.1002165.
6. Anne L Plant, L. E. Locascio, W. E. May and P. D. Gallagher, *Nat. Methods*, 2015, **11**, 895-898.
7. J. L. Holmes and R. S. Pollenz, *Molecular Pharmacology*, 1997, **52**, 202-211.
8. D. Bond, D. A. Primrose and E. Foley, *Biological Procedures Online*, 2008, **10**, 20-28.
9. V. Bergendahl, B. T. Glaser and R. R. Burgess, *Journal of Immunological Methods*, 2003, **277**, 117-125.
10. G. P. Smith and V. A. Petrenko, *Chemical reviews*, 1997, **97**, 391-410.
11. H. M. Geysen, S. J. Rodda and T. J. Mason, *Molecular immunology*, 1986, **23**, 709-715.
12. G. L. Morris, H. C. Cheng, J. Colyer and J. H. Wang, *Journal of Biological Chemistry*, 1991, **266**, 11270-11275.
13. S. Yokoe, M. Asahi, T. Takeda, K. Otsu, N. Taniguchi, E. Miyoshi and K. Suzuki, *Glycobiology*, 2010, **20**, 1217-1226.
14. T. Suzuki and J. H. Wang, *Journal of Biological Chemistry*, 1986, **261**, 7018-7023.
15. K. Oxenoid and J. J. Chou, *Proceedings of the National Academy of Sciences of the United States of America*, 2005, **102**, 10870-10875.
16. G. A. Drago and J. Colyer, *Journal of Biological Chemistry*, 1994, **269**, 25073-25077.
17. C. Mundina-Weilenmann, L. Vittone, M. Ortale, G. C. de Cingolani and A. Mattiazzi, *The Journal of biological chemistry*, 1996, **271**, 33561-33567.
18. M. W. Vetting, S. S. Hegde, K. Z. Hazleton and J. S. Blanchard, *Protein Science*, 2007, **16**, 755-760.
19. N. Floyd, B. Vijaykrishnan, A. R. Koeppe and B. G. Davis, *Angewandte Chemie-International Edition*, 2009, **48**, 7798-7802.
20. J. M. Chalker, G. J. L. Bernardes and B. G. Davis, *Accounts of Chemical Research*, 2011, **44**, 730-741.
21. G. J. L. Bernardes, J. M. Chalker, J. C. Errey and B. G. Davis, *Journal of the American Chemical Society*, 2008, **130**, 5052-5053.
22. J. Wang, S. M. Schiller and P. G. Schultz, *Angewandte Chemie International Edition*, 2007, **46**, 6849-6851.
23. F. P. Seebeck and J. W. Szostak, *Journal of the American Chemical Society*, 2006, **128**, 7150-7151.
24. J. M. Chalker, S. B. Gunnoo, O. Boutureira, S. C. Gerstberger, M. Fernandez-Gonzalez, G. J. L. Bernardes, L. Griffin, H. Hailu, C. J. Schofield and B. G. Davis, *Chemical Science*, 2011, **2**, 1666-1676.
25. J. C. Aon, R. J. Caimi, A. H. Taylor, Q. Lu, F. Oluboyede, J. Dally, M. D. Kessler, J. J. Kerrigan, T. S. Lewis, L. A. Wysocki and P. S. Patel, *Applied and Environmental Microbiology*, 2008, **74**, 950-958.
26. R. A. Bednar, *Biochemistry*, 1990, **29**, 3684-3690.